top of page



Cardiovascular Devices Review 2024

This report highlights company performance in select Cardiovascular (CV) device segments • Revenue performance of key public companies, as well as M&A and investments: Abbott, Boston Scientific, Edwards Lifesciences, J&J, and Medtronic • Overview of VC investments, M&A and IPOs for select segments of interest: Atrial fibrillation, mechanical circulatory support, cardiac monitoring, cardiac rhythm management (CRM), and transcatheter valves

Robotic Assisted Surgery Landscape Review 2024

This report highlights analysis and key trends in the Robotic Assisted Surgery (RAS) Landscape. Included are development stage and funding status of RAS platforms in key segments, including surgical platforms and positioning/navigation-enabled platforms, as well as global market size, market trends, and healthcare investments.

Digital Health Market Intelligence

This report analyzes revenue growth and investment trends across key Digital Health segments and stakeholders (including Payers, the Big Four Tech and Top MedTech Companies). The Spotlight is Value-based Care, A Digital Health Proving Ground, which highlights how Digital Health can be used to bridge gaps and drive outcomes.

Highlights Q3 2023

Prostate Biopsy and Mapping Augmented Reality Surgical Navigation  Bioprocessing Quality Control Endoluminal Robotics Academic Medical Center Enteral Feeding Intraoperative Molecular Imaging Medical Device Contract Manufacturing Clinical Research Organization

Highlights Q2 2023

Robotic Surgery Hypoglycemia Sacroiliac Joint Pain Pharma Commercialization Services Academic Medical Center Clinical Research Organization Health Insurance TPA Medical Legal Regulatory (MLR) Consulting

Opportunities in Precision Medicine for Neuroscience 2024

This deep dive looks at investment trends in precision medicine, the rationale for multicomponent biomarkers for neurological disorders, and examines the potential impact of PM approaches for Alzheimer's disease.

Life Science Tools and Diagnostics Market Intelligence Report

This report provides a review of revenue growth for public companies in FSI’s Life Science Tools and Diagnostics segments from 2019 – 2023 as well as LS Tools and Dx investments and exits: - Revenue performance of public companies in life science tools (including bioprocessing, diversified, and omics-related segments) and diagnostics (including genetic, cancer, and diversified IVD segments) - Overview of VC investments, M&A, and IPOs in LS Tools and Dx - Preview for upcoming Precision Medicine in Neuroscience report

Highlights Q4 2023

Point-of-Care Molecular Diagnostics GLP-1 Agonists and Cardiac Procedures Digital Health – Specialty Telehealth Bioprocessing Quality Control Clinical Lab Services Health System Innovation Group CRO Services for Biosimilars Development Clinical Research Organization Multi-indication Surgical Robotic Breast Localization and Lymphatic Mapping Pharma Commercialization

Digital Health Review H1 2023

Key Digital Health trends and a spotlight on Surgery: The Intersection of Digital Health / AI and Medtech. Investments in Digital Health (Medtech, the Big Four Tech and Payers). Analysis of Digital Health VC investments, M&A and IPOs.

Highlights Q1 2023

Chronic Limb Threatening Ischemia Pharma Commercialization Services Intraoperative Molecular Imaging Laparoscopic Surgery Smart Abdominal Binder Digital Health – Remote Patient Monitoring Protein Characterization Clinical Research Organization Senior Living


News (new).png

Join our email list to be informed of FSI insights

Thanks for submitting!

bottom of page